Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Archive ouverte

Robin, Marie | de Wreede, Liesbeth C. | Wolschke, Christine | Schetelig, Johannes | Eikema, Diderik-Jan | van Lint, Maria Teresa | Knelange, Nina | Beelen, Dietrich | Brecht, Arne | Niederwieser, Dietger | Vitek, Antonin | Bethge, Wolfgang | Arnold, Renate | Finke, Jurgen | Volin, Liisa | Yakoub-Agha, Ibrahim | Nagler, Arnon | Poire, Xavier | Einsele, Hermann | Chevallier, Patrice | Holler, Ernst | Ljungman, Per | Robinson, Stephen | Radujkovic, Aleksandar | Mclornan, Donal | Chalandon, Yves | Kroger, Nicolaus

Edité par CCSD ; Ferrata Storti Foundation -

International audience. Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion